GlassScriptPhysician profile
Sonia Cajigal
NPI 1720308448
$10,262.97
in general payments reported to CMS, 2019-2025
27 companies · $2,487 in 2025
The $2,487 reported for 2025 was more than what a typical Allergy & Immunology provider received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $243 · 2020: $300 · 2021: $735 · 2022: $1,917 · 2023: $3,009 · 2024: $1,572 · 2025: $2,487.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,064 · Consulting Fee: $2,934 · Education: $54.95 · Travel and Lodging: $15.55.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,063.51 |
| Consulting Fee | $2,934.00 |
| Education | $54.95 |
| Travel and Lodging | $15.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $2,660.84 | 2020-2025 | |
| Genentech USA, INC. | $1,359.57 | 2021-2024 | Xolair |
| Glaxosmithkline, LLC. | $1,315.24 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Regeneron Healthcare Solutions, INC. | $845.92 | 2019-2025 | Dupixent |
| Astrazeneca Pharmaceuticals LP | $775.85 | 2019-2024 | Tezspire, Fasenra, Airsupra |
| Nevro Corp. | $632.67 | 2022-2024 | Senza |
| Takeda Pharmaceuticals U.S.A., INC. | $492.84 | 2021-2025 | Cuvitru, Hyqvia, Takhzyro |
| Optinose US, INC. | $413.14 | 2020-2025 | |
| Spinal Simplicity, LLC | $388.13 | 2022 | |
| Novartis Pharmaceuticals Corporation | $229.79 | 2019-2025 | |
| Kaleo, INC. | $225.73 | 2019-2024 | Auvi-Q |
| Globus Medical, INC. | $175.00 | 2025 | Senza |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $118.82 | 2023 | Relistor, Xifaxan |
| Sanofi-Aventis U.S. LLC | $116.94 | 2022-2023 | |
| Amgen INC. | $100.10 | 2021-2024 | Tezspire |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Csl Behring | $93.28 | 2023-2025 | Hizentra |
| Abbvie INC. | $61.91 | 2021 | |
| Pfizer INC. | $48.12 | 2019-2024 | |
| Grifols USA, LLC | $44.03 | 2022-2024 | Xembify |
| Aimmune Therapeutics, INC. | $41.95 | 2021-2022 | |
| Eyevance Pharmaceuticals LLC | $35.74 | 2021 | |
| Leo Pharma INC. | $20.57 | 2023 | Adbry |
| Teva Pharmaceuticals USA, INC. | $18.04 | 2021 | |
| Merck Sharp & Dohme LLC | $17.40 | 2021 | |
| Alk-Abello, INC | $13.78 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $13.76 | 2019 | |
| Organon LLC | $3.81 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sonia Cajigal listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.